secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2025-06-11T23:59:59+00:00
Accession:  0000950170-25-084650
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Therapeutics enters commercialization agreement with EVERSANA for ORLYNVAH in US
--------------------------------------------------------------------------------

- Eversana will be exclusive provider of sales, marketing, logistics, regulatory, and medical affairs services for ORLYNVAH.
- ITUS retains legal, regulatory, manufacturing, and books sales; pays fees and expenses per statements of work.
- Term is 5 years from commercial launch; either party can terminate for material breach, insolvency, or certain law changes.
- ITUS or change-of-control counterparty may terminate upon paying specified fees; Eversana can terminate if ORLYNVAH is withdrawn.
- Agreement includes customary confidentiality, indemnification, and liability limitations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017025084650/0000950170-25-084650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017025084650/itrm-20250606.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-084650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer